Expert Interview
A look into the clinical landscape for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Also reviewing the recent data from Alexion's oral factor D inhibitor, Danicopan, an add on to Ultomiris or Soliris
Ticker(s): AZN, APLSInstitution: Dana Farber Cancer Institute
- Professor of Medicine, Harvard Medical School & Chief Emeritus of the Stem Cell Transplant Program of the Dana-Farber/Brigham and Women's Cancer Center.
- Treats 30 - 40 patients with cGVHD per year and 30 patients with Paroxysmal Nocturnal Hemoglobinuria each month.
- Research focuses on Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect, aplastic anemia, and PNH.
Please describe your background and practice setting
Added By: ben_adminHave you treated any patients with Empevali? If not, do you anticipate prescribing for patients in the future?
Do you see a difference in transfusion rates amongst branded agents? Is this an unmet need?
Added By: ben_adminDo you think future treatments will focus on the C5 or C3 mechanism of action in disrupting the complement system?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
